Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cero Therapeutics Holdings Inc. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners across an equal number of distinct art units. This structure shows that each case is undergoing a separate review process by different personnel in different administrative departments. The lack of concentration suggests that the company's current biotechnology applications fall under different specialized jurisdictions at the USPTO.
CANELLA, KAREN A is the busiest examiner for the company, currently managing 1 pending office action. With 2 total pending office actions, the workload is divided between the examiners. The company must therefore manage prosecution across multiple art units within the biotechnology field. For the practitioner, this requires a strategy that accounts for the specific preferences and technical requirements of each examiner, as no single unit holds a majority of the active cases. Each matter must be prosecuted based on its own unique administrative and technical context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292782 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CANELLA, KAREN A | — |
| 18041200 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | LUNDE, GRACE HENRY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292782 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CANELLA, KAREN A | 1643 | §112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18041200 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | LUNDE, GRACE HENRY | 1641 | §112DP | Final Rejection | — | Pending | Feb 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCero Therapeutics Holdings Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Karen A Canella has the most, with 1 of Cero Therapeutics Holdings Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
